Phone: 1.510.856.5600|info@anthera.com

Press Releases

 
Press Releases
  Date Title and Summary View
Jun 15, 2016
May 30, 2016
May 9, 2016
SOLUTION clinical study of Sollpura™ expanded to Europe, Israel and Canada in addition to ongoing US enrollmentCraig Thompson named as President and Chief Operating OfficerAppointment of Dr. James Pennington to Interim Chief Medical OfficerEnrollment of BRIGHT-SC Phase 2 clinical study in IgA Nephropathy completedBulk manufacturing campaign f...
Apr 27, 2016
HAYWARD, Calif., April 27, 2016 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) today announced the appointment of Brent Furse to its Board of Directors. Mr. Furse has over 25 years of healthcare commercial leadership experience with extensive experience in the areas of sales and marketing, commercial product launch and partn...
Mar 10, 2016
SOLUTION clinical study of oral Sollpura™ enrollment to begin soon in EuropeData from BRIGHT-SC study in IgA nephropathy planned for Q2 2016Addition of Craig Thompson as President and Chief Operating OfficerAppointment of Dr. James Pennington to Interim Chief Medical Officer HAYWARD, Calif., March 10, 2016 (GLOBE NEWSWIRE) -- Anthera Phar...
Mar 7, 2016
HAYWARD, Calif., March 07, 2016 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) today announced the appointment of James Pennington, M.D. as interim Chief Medical Officer following the Company's acceptance of Colin Hislop's resignation effective April 1st, 2016. "Our development programs have progressed extensively during Col...
Jan 5, 2016
HAYWARD, Calif., Jan. 05, 2016 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc.  (Nasdaq:ANTH) today announced the appointment of Craig Thompson as President and Chief Operating Officer.  In this role Mr. Thompson will oversee both of Anthera's late stage development programs and commercial preparation efforts.  Anthera also announced the appoin...
Nov 6, 2015
Closed $29 million public offering in July including full exercise of underwriters' option to purchase additional sharesCompleted capsule manufacturing in support of the SOLUTION clinical studyInitiated the SOLUTION clinical study of oral Sollpura™ To regain all Japan rights to blisibimod following termination of Asia partnership HAYWARD, Ca...
Oct 28, 2015
HAYWARD, Calif., Oct. 28, 2015 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced the Company's attendance at the following healthcare conferences: November 4th, 2015, Mr. Paul F. Truex, President and Chief Executive Officer, will host one-on-one meetings at the 2015 Citi Global Healthcare Conference at the Palac...
Oct 2, 2015
Study to enroll approximately 130 patients with exocrine pancreatic insufficiency More than 50 clinical sites around the United States and Europe are expected to participate Anthera to host reception at the North American Cystic Fibrosis Conference to discuss the SOLUTION program. HAYWARD, Calif., Oct. 2, 2015 (GLOBE...
Page:
1
... NextLast
= add release to Briefcase
Print Friendly